"The Price of Life" Reporting back on film screening and panel discussion
Published: 29 November 2023
In November 2023, the Health Economics and Health Technology Assessment (HEHTA) team was pleased to host a community engagement event exploring decision-making in health technology assessment (HTA), aimed at demystifying processes and considering challenges
On 22 November 2023, around 100 people attended a HEHTA-hosted community engagement event at UofG's Advanced Research Centre (ARC), exploring decision-making in health technology assessment (HTA).
The aim of the event was to demystify HTA processes, and to consider some of the challenges of decision-making.
Joined by around 100 attendees, the evening started with a screening of "The Price of Life" a documentary by the award-winning film-maker Adam Wishart. It focuses on decision-making by NICE on Revlimid (lenalidomide), a drug for multiple myeloma, and captures the perspectives of a range of stakeholders, including patients and their families, and clinicians.
This was followed by a panel discussion on HTA decision-making on drugs for cystic fibrosis. One of our researchers, Ryan Mulholland, introduced the discussion by providing some context on recent appraisals by NICE and SMC on the CFTR modulators, Kalydeco, Orkambi, Symkevi, and Kaftrio for cystic fibrosis. The panel, chaired by our deputy director Prof Emma McIntosh, consisted of:
- Thomas Ferguson, a person living with cystic fibrosis and involved in campaigning for access to CFTR modulators in Scotland
- Marion Ferguson, campaigner for access to CFTR modulators in Scotland
- Jeane Freeman, Dean of Strategic Community Engagement and Economic Development, and former Scottish Cabinet Secretary for Health and Sport
- Prof Gordon MacGregor, consultant in respiratory medicine specialising in cystic fibrosis
- Prof Olivia Wu, Director of HEHTA
In discussing decision-making on these cystic fibrosis drugs, panellists offered insightful and compelling contributions on a range of areas, including:
- the impact of cystic fibrosis on patients and carers
- the benefits of CFTR modulators
- the roles of HTA bodies and governments in price negotiations, measurement of health outcomes, perspectives in economic evaluations, and spillover effects.
Finally, there was a range of thought-provoking questions to the panel from our engaged audience.
Following the success of this event, the HEHTA team are keen to develop further similar events in the future. If you would like to be updated on future events, please subscribe to our mailing list by contacting shw-hehta@glasgow.ac.uk
Ryan Mulholland
Research Assistant (Health Economics and Health Technology Assessment)
Find out about other HEHTA events
First published: 29 November 2023